Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. [electronic resource]
Producer: 20111103Description: 1241-51 p. digitalISSN:- 1538-8514
- Animals
- Antineoplastic Agents -- pharmacology
- Benzenesulfonates -- pharmacology
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cells, Cultured
- DNA-Binding Proteins -- genetics
- Dose-Response Relationship, Drug
- Down-Regulation -- drug effects
- Endonucleases -- genetics
- Endothelial Cells -- drug effects
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Mice
- Mice, SCID
- Neoplasms -- drug therapy
- Neoplastic Stem Cells -- drug effects
- Neovascularization, Pathologic -- drug therapy
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Pyridines -- pharmacology
- Radiation Tolerance -- drug effects
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Sorafenib
- Tumor Burden -- drug effects
- X-ray Repair Cross Complementing Protein 1
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.